Sionna Therapeutics, Inc. Common Stock (NASDAQ:SION) — Market Cap & Net Worth
Market Cap & Net Worth: Sionna Therapeutics, Inc. Common Stock (SION)
Sionna Therapeutics, Inc. Common Stock (NASDAQ:SION) has a market capitalization of $316.79 Million ($316.79 Million) as of September 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #14621 globally and #3467 in its home market, demonstrating a -3.56% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Sionna Therapeutics, Inc. Common Stock's stock price $7.04 by its total outstanding shares 44998073 (45.00 Million). Also see Sionna Therapeutics, Inc. Common Stock assets under control for a full breakdown of the balance sheet.
Sionna Therapeutics, Inc. Common Stock Market Cap History: 2025 to 2026
Sionna Therapeutics, Inc. Common Stock's market capitalization history from 2025 to 2026. Data shows change from $1.85 Billion to $316.79 Million (-54.59% CAGR). Also see SION cash generation efficiency for how efficiently the company converts equity into cash flow.
Index Memberships
Sionna Therapeutics, Inc. Common Stock is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.01% | #398 of 976 |
Weight: Sionna Therapeutics, Inc. Common Stock's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Sionna Therapeutics, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Sionna Therapeutics, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check latest Sionna Therapeutics, Inc. Common Stock stock price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of SION by Market Capitalization
Companies near Sionna Therapeutics, Inc. Common Stock in the global market cap rankings as of September 17, 2026. Review SION intangible-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Sionna Therapeutics, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
Sionna Therapeutics, Inc. Common Stock Historical Marketcap From 2025 to 2026
Between 2025 and today, Sionna Therapeutics, Inc. Common Stock's market cap moved from $1.85 Billion to $ 316.79 Million, with a yearly change of -54.59%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $316.79 Million | -82.89% |
| 2025 | $1.85 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Sionna Therapeutics, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $316.79 Million USD |
| MoneyControl | $316.79 Million USD |
| MarketWatch | $316.79 Million USD |
| marketcap.company | $316.79 Million USD |
| Reuters | $316.79 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Sionna Therapeutics, Inc. Common Stock
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109,… Read more